Host antiviral factors hijack furin to block SARS-CoV-2, ebola virus, and HIV-1 glycoproteins cleavage
ABSTRACTViral envelope glycoproteins are crucial for viral infections. In the process of enveloped viruses budding and release from the producer cells, viral envelope glycoproteins are presented on the viral membrane surface as spikes, promoting the virus's next-round infection of target cells. However, the host cells evolve counteracting mechanisms in the long-term virus-host co-evolutionary processes. For instance, the host cell antiviral factors could potently suppress viral replication by targeting their envelope glycoproteins through multiple channels, including their intracellular synthesis, glycosylation modification, assembly into virions, and binding to target cell receptors. Recently, a group of studies discovered that some host antiviral proteins specifically recognized host proprotein convertase (PC) furin and blocked its cleavage of viral envelope glycoproteins, thus impairing viral infectivity. Here, in this review, we briefly summarize several such host antiviral factors and analyze their roles in reducing furin cleavage of viral envelope glycoproteins, aiming at providing insights for future antiviral studies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Emerging Microbes and Infections - 12(2023), 1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Changqing Yu [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antiviral factors |
|---|
| doi: |
10.1080/22221751.2022.2164742 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ000645303 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ000645303 | ||
| 003 | DE-627 | ||
| 005 | 20240414125242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2022.2164742 |2 doi | |
| 035 | |a (DE-627)DOAJ000645303 | ||
| 035 | |a (DE-599)DOAJ6156d643d80847419dd89509169c589b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Changqing Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Host antiviral factors hijack furin to block SARS-CoV-2, ebola virus, and HIV-1 glycoproteins cleavage |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACTViral envelope glycoproteins are crucial for viral infections. In the process of enveloped viruses budding and release from the producer cells, viral envelope glycoproteins are presented on the viral membrane surface as spikes, promoting the virus's next-round infection of target cells. However, the host cells evolve counteracting mechanisms in the long-term virus-host co-evolutionary processes. For instance, the host cell antiviral factors could potently suppress viral replication by targeting their envelope glycoproteins through multiple channels, including their intracellular synthesis, glycosylation modification, assembly into virions, and binding to target cell receptors. Recently, a group of studies discovered that some host antiviral proteins specifically recognized host proprotein convertase (PC) furin and blocked its cleavage of viral envelope glycoproteins, thus impairing viral infectivity. Here, in this review, we briefly summarize several such host antiviral factors and analyze their roles in reducing furin cleavage of viral envelope glycoproteins, aiming at providing insights for future antiviral studies. | ||
| 650 | 4 | |a Antiviral factors | |
| 650 | 4 | |a furin | |
| 650 | 4 | |a viral glycoprotein | |
| 650 | 4 | |a cleavage | |
| 650 | 4 | |a SARS-CoV-2 | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Guosheng Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Qiang Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Jingbo Zhai |e verfasserin |4 aut | |
| 700 | 0 | |a Mengzhou Xue |e verfasserin |4 aut | |
| 700 | 0 | |a Qiang Li |e verfasserin |4 aut | |
| 700 | 0 | |a Yuanhua Xian |e verfasserin |4 aut | |
| 700 | 0 | |a Chunfu Zheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Emerging Microbes and Infections |d Taylor & Francis Group, 2013 |g 12(2023), 1 |w (DE-627)DOAJ00011538X |x 22221751 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |
| 856 | 4 | 0 | |u https://doi.org/10.1080/22221751.2022.2164742 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/6156d643d80847419dd89509169c589b |z kostenfrei |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/10.1080/22221751.2022.2164742 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2222-1751 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 | ||